Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
Product revenue $ 204 $ 167 $ 411 $ 264
Costs of revenue 163 133 329 212
Gross profit 41 34 82 52
Operating expenses:        
Research and development 1,068 836 2,061 1,554
General and administrative 826 615 1,591 1,586
Sales and marketing 131 105 268 164
Total operating expenses 2,025 1,556 3,920 3,304
Loss from operations (1,984) (1,522) (3,838) (3,252)
Other income (expenses):        
Interest expense (1) (2) (1) (2)
Interest income 85 115 189 237
Change in fair value of derivative liabilities (2,128) 631 2,037 610
Offering costs (1,246)
Other income, net 48 48
Total other income (expense), net (2,044) 792 979 893
Net loss before income taxes (4,028) (730) (2,859) (2,359)
Provision for income taxes
Net loss (4,028) (730) (2,859) (2,359)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock (207) (2,358) (9,491) (2,358)
Net loss attributable to common stockholders $ (4,235) $ (3,088) $ (12,350) $ (4,717)
Net loss per share - basic and diluted        
Basic - net loss $ (0.33) $ (0.78) $ (0.32) $ (2.84)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock (0.02) (2.53) (1.05) (2.84)
Basic - attributable to common stockholders (0.35) (3.31) (1.37) (5.68)
Diluted - net loss (0.33) (1.46) (0.45) (3.58)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock (0.02) (2.53) (0.84) (2.84)
Diluted - attributable to common stockholders $ (0.35) $ (3.99) $ (1.29) $ (6.42)
Weighted average common shares outstanding:        
Basic 12,120,420 931,859 9,070,655 829,724
Diluted 12,120,420 931,859 11,314,252 829,724